Literature DB >> 11920641

Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.

Do-Sun Byun1, Kwon-Seok Chae, Byung-Kyu Ryu, Min-Goo Lee, Sung-Gil Chi.   

Abstract

p53R2, a recently identified putative tumor suppressor located at 8q23.1, encodes a protein with striking similarity to a small subunit of ribonucleotide reductase. p53R2 is directly induced by wild-type p53 and involved in the p53 checkpoint for repair of damaged DNA, raising the possibility that mutational inactivation of p53R2 may contribute to the development and progression of human malignancies. To explore the p53R2's candidacy for a suppressor in gastric tumorigenesis, we examined the expression and mutation status of p53R2 in 166 gastric specimens including 90 primary adenocarcinomas and 15 cell lines. In response to genotoxic damages, p53R2 transcription was clearly activated in wild-type but not mutant-type p53-carrying cells while basal expression of p53R2 in undamaged cells showed no association with the mutational status of p53. Host cell reactivation assay revealed that p53R2 enhances DNA repair efficiency and plays a role in the p53-mediated repair of damaged DNA, whereas no significant effect of p53R2 on cell growth and apoptosis was detected in flow cytometry and [(3)H]thymidine incorporation assays. p53R2 transcript was expressed in all normal and tumor tissues and its expression levels were not significantly different between normal and malignant carcinoma tissues. p53R2 expression showed no correlation with stage, grade and histological types of tumors. Moreover, no tumor-specific reduction of p53R2 was detected in 30 matched sets. Mutational analysis of p53R2 in 105 carcinomas including 15 cell lines also failed to detect any evidences for genomic deletion or somatic mutations leading to amino acid substitutions or frameshift whereas 31% (28 of 90) of the same primary tumors showed p53 alterations. Whereas 82% (23 of 28) of the mutant p53-carrying primary tumors expressed abnormally low p21(Waf1), no association of p53R2 expression with the p53 status was recognized, suggesting that basal transcription of p53R2 is regulated through the p53-independent mechanism. Collectively, our study indicates that although p53R2 is induced in a p53-dependent manner and involved the p53-mediated DNA repair in gastric epithelial cells, it is not a critical target of genetic inactivation in gastric tumorigenesis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920641     DOI: 10.1002/ijc.10253

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells.

Authors:  Karin Edvardsson; Anders Ström; Philip Jonsson; Jan-Åke Gustafsson; Cecilia Williams
Journal:  Mol Endocrinol       Date:  2011-04-14

2.  A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions.

Authors:  Henna Tyynismaa; Emil Ylikallio; Mehul Patel; Maria J Molnar; Ronald G Haller; Anu Suomalainen
Journal:  Am J Hum Genet       Date:  2009-08-06       Impact factor: 11.025

3.  p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.

Authors:  Keqiang Zhang; Jun Wu; Xiwei Wu; Xiaochen Wang; Yan Wang; Ning Zhou; Mei-ling Kuo; Xiyong Liu; Bingsen Zhou; Lufen Chang; David Ann; Yun Yen
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

4.  Novel genetic variations of the p53R2 gene in patients with colorectal adenoma and controls.

Authors:  Zong-Lin Deng; Da-Wen Xie; Roberd M Bostick; Xi-Jiang Miao; You-Ling Gong; Jin-Hui Zhang; Michael J Wargovich
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

5.  The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma.

Authors:  H Okumura; S Natsugoe; M Matsumoto; Y Mataki; H Takatori; S Ishigami; S Takao; T Aikou
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

6.  A novel RRM2B mutation associated with mitochondrial DNA depletion syndrome.

Authors:  Monica Fumagalli; Dario Ronchi; Maria Francesca Bedeschi; Arianna Manini; Gloria Cristofori; Fabio Mosca; Robertino Dilena; Monica Sciacco; Simona Zanotti; Daniela Piga; Gianluigi Ardissino; Fabio Triulzi; Stefania Corti; Giacomo P Comi; Leonardo Salviati
Journal:  Mol Genet Metab Rep       Date:  2022-06-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.